TÉMOIGNAGES/RÉFÉRENCES

Nos témoignages d’experts fournissent une brève analyse ainsi que des recommandations sur les enjeux actuels relatifs aux risques.

Change selection to sort. Sort by:   
Benchmarking Trends—Property 'All Risk' Renewal Rates Continue to Climb in January 2012
07 février 2012  |  Vues: 124 |  Commentaires: 0  | Article Rating
Benchmarking Trends—Property 'All Risk' Renewal Rates Continue to Climb in January 2012
Changes in rates were relatively modest in the fourth quarter of 2011; just over half of accounts renewed with rate changes between minus 10 percent and plus 10 percent.   >>
Risk Spotlight: Preparing, Managing, and Responding to Catastrophic Claims
01 février 2012  |  Vues: 83 |  Commentaires: 0 
Risk Spotlight: Preparing, Managing, and Responding to Catastrophic Claims
One of the principal lessons from 2011’s catastrophes is the importance of the preparation done before disaster strikes.  >>
Sorry, no photo is available.
25 janvier 2012  |  Vues: 317 |  Commentaires: 0  | Article Rating
Enquête « Les juristes et la gestion des risques »
Marsh, l’AFJE et l’ESSCA, ont mené en 2011, une enquête sur le thème « Dirigeants et juristes : la gestion des risques en entreprise ».Cette enquête, dont les résultats ont été pré...  >>
Environmental Exposures Put Financial Institutions at Risk
05 janvier 2012  |  Vues: 67 |  Commentaires: 0 
Environmental Exposures Put Financial Institutions at Risk
We discuss several emerging environmental issues financial institutions' risk managers should keep in mind.  >>
Sorry, no photo is available.
23 mai 2011  |  Vues: 55 |  Commentaires: 0 
Nuclear Insurance Market update
As with other developed nuclear power countries, Japan has established a nuclear liability regime to ensure the public has a clear path to seek recovery for damages from a nuclear ...  >>
Sorry, no photo is available.
12 mai 2011  |  Vues: 55 |  Commentaires: 0 
European Commission's plan to revise the Clinical Trials Directive in 2012
Marsh has provided an update on the process of seeking feedback on proposed changes to the European Commission's Clinical Trials Directive (DIR 2001/20/EC).  >>